MedTrace Logo

Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults

NCT00199082 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 650

Last updated 2022-08-19

No results posted yet for this study

Summary

The study evaluates the efficacy and tolerability of alternating short cycles of high-dose and conventional chemotherapy in combination with rituximab in CD20 positive patients, followed by local radiation therapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. A dose-reduced regimen is offered for patients estimated to be over 55 years, biologically.

Conditions

  • Burkitt's Lymphoma
  • Burkitt's Leukemia
  • Mediastinal Neoplasms
  • Lymphoblastic Lymphoma
  • Large Cell Anaplastic Lymphoma

Interventions

DRUG

Adriamycin

DRUG

Cyclophosphamide

DRUG

Cytarabine

DRUG

Dexamethasone/Prednisolone

DRUG

VP16

DRUG

Ifosfamide

DRUG

Methotrexate

DRUG

G-CSF

DRUG

Rituximab

DRUG

Vincristine/Vindesine

PROCEDURE

Irradiation (in specific conditions)

Sponsors & Collaborators

  • Nicola Goekbuget

    lead OTHER

Principal Investigators

  • Nicola Goekbuget, Dr. med. · University Hospital of Frankfurt (Main)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00199082 on ClinicalTrials.gov